22 results about "Interleukin 6" patented technology

The application discloses an electrochemical sensor for detecting IBD protein markers and a preparation method thereof. The electrochemical sensor is composed of a CNT-embedded semi-cured PDMS flexible substrate, deposited gold nanoparticles and a nucleic acid sensing layer. The nucleic acid sensing layer comprises a tumor necrosis factor-alpha sensor, an interleukin 6 sensor, an interleukin 8 sensor, a transforming growth factor beta 1 sensor, a reference electrode and a counter electrode. The tumor necrosis factor-alpha sensor, the interleukin 6 sensor, the interleukin 8 sensor and the transforming growth factor beta 1 sensor all adopt single-stranded aptamers modified by a signal molecule methylene blue, and the nucleotide sequences corresponding to the single-stranded aptamers are SEQ ID NO. 1-4. The application can improve the modulus matching of the sensor and human tissue and excellent biocompatibility, realize accurate detection of low-concentration biomarkers and stable signal output of the sensor under a strain working condition.

The invention provides a special culture medium for prostate cancer organoid and a culture method thereof, and belongs to the technical field of biological medicines. The special culture medium for the prostatic cancer organoid is composed of a basic culture medium and a culture additive, and the basic culture medium does not contain exogenously added Noggin recombinant protein and R-spondin recombinant protein. The culture additive is prepared from a basic fibroblast growth factor, a keratinocyte growth factor, a fibroblast growth factor 10, insulin, a p38MAPK signal channel inhibitor, an insulin-like growth factor 1, B27, nicotinamide, N-acetylcysteine, hydrocortisone, a ROCK kinase inhibitor, retinoic acid, interleukin 6, prostaglandin E2, a eriocin and androgen. According to the special culture medium for the prostatic cancer organoid, the culture success rate is increased while the cost is reduced.

The invention discloses a kit for detecting susceptibility and severity of children acute respiratory distress syndrome, and relates to the technical field of biomedical detection. The kit comprises a detection reagent combination and a standardized reference system, the detection reagent combination is prepared from specific binding angiogenin 2, a soluble advanced glycosylation end product receptor, pulmonary surfactant protein D, a soluble tumor necrosis factor receptor 1, interleukin 6, interleukin 8, a plasminogen activator inhibitor 1 and a capture and detection antibody of III type procollagen N-terminal peptide. The primer pair and the probe are used for specifically amplifying a single nucleotide polymorphism site rs4073 in a promoter region of the interleukin 8 gene; the standardized reference product system comprises gradient standard products covering the physiological concentration dynamic ranges of the markers on the 0th day, the 3rd day and the 7th day of morbidity; the kit is used for early-stage precise layering and dynamic prognosis evaluation of the acute respiratory distress syndrome of children.

The subject matter described herein relates to peptides that bind to the human AT-rich interactive domain 5A protein (Arid5a). The subject matter described herein also relates to methods of inhibiting Interleukin 6 (IL-6) production in a subject, the method comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of any one of the peptides disclosed herein.

A recombinant nucleic acid molecule is encoded at least by an ORF to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one hairpin loop structure and a first promoter. The at least one hairpin loop structure is formed by one or more short hairpin RNA sequences. The at least one hairpin loop structure regulates an amount of Interleukin 6 (IL6) cytokine during immunotherapy. The first promoter is disposed upstream of the at least one hairpin loop structure.

This invention provides an antibody combination for detecting interleukin-6 (IL-6), comprising a first antibody and / or a second antibody, each possessing a unique CDR fragment. Specific applications of this antibody combination are also provided. The advantages of this invention are that the antibody combination exhibits strong affinity for the IL-6 antigen, high detection sensitivity, ease of use, and rapid and stable detection. The concentration of IL-6 in normal human blood is approximately 4.2 pg / mL. Existing conventional low-affinity antibodies are insufficient for effective detection in this situation. However, the high-affinity antibody combination and the IL-6 quantitative detection kit containing this antibody combination using a double-antibody sandwich method provided by this invention can effectively achieve the quantitative detection of ultra-low concentrations of IL-6. Verification shows that the kit's sensitivity can reach 0.9 pg / mL.

The application discloses a kit for detecting interleukin 6 and preparation and application. The kit comprises magnetic microspheres coated first antibodies and tracer marker labeled second antibodies. The first antibodies are 12H6 with a catalog number of DA011, IL-6-55E9 with a catalog number of P1810035 of Jin Sui, or IL-6-01 with a catalog number of 20180915 of Gelin. The second antibodies are 15H5 with a catalog number of DA012, IL-6-55C6 with a catalog number of P1904008 of Jin Sui, or IL-6-02 with a catalog number of 20180919 of Gelin. The application has the advantages of simple operation, low cost, short detection time, high sensitivity and wide linear range, and can realize full-automatic, rapid, sensitive and quantitative detection of the concentration of IL-6 in samples.

The invention provides a composition for improving bone joints and promoting bone health as well as a preparation method and application thereof, and relates to the technical field of compositions. The composition is prepared from N-acetylglucosamine and a turmeric extract. The composition can improve the differentiation activity of cartilage precursor cells, effectively promote synthesis of cartilage matrixes, increase the structural construction ability of cartilage tissues, reverse expression down-regulation of cartilage synthesis markers, down-regulate abnormally high expression of cartilage decomposition markers and maintain metabolic balance of cartilage synthesis and decomposition, and has the effects of improving the cartilage tissue differentiation activity and improving the cartilage tissue differentiation activity. Abnormal high secretion of tumor necrosis factors alpha and interleukin 6 in LPS-induced cartilage cells is reduced, and the effects of resisting inflammation, resisting cartilage degradation and maintaining cartilage metabolism balance are achieved.

A recombinant nucleic acid molecule is encoded at least by an ORF to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one hairpin loop structure and a first promoter. The hairpin loop structure regulates an amount of Interleukin 6 (IL6) cytokine during immunotherapy. The hairpin loop structure is formed by at least two short hairpin RNA sequences and at least one microRNA30 sequence. The short hairpin RNA sequences form a stem of the hairpin loop structure. The microRNA30 sequence forms a loop of the hairpin loop structure. The first promoter is disposed upstream of the hairpin loop structure.

Disclosed in the present invention are antifungal compounds, a preparation method therefor, and the use thereof. The compounds have the following general formula I, wherein L represents a linking moiety, referring to a small molecule fragment, and Ar represents a heterocyclic ring or a substituted heterocyclic ring. The series of compounds of the present invention can better bind to an enzyme target by means of various interaction forces, thereby exhibiting good activity; and the compounds exhibit excellent activity in both in vitro experiments and animal experiments, the activity of most of the compounds against Candida albicans being better than that of fluconazole. In addition, the series of compounds have anti-inflammatory effects while eliminating fungal infections; and compared with voriconazole, the series of compounds of the present invention can remarkably down-regulate the expression of an inflammatory factor interleukin 6.

This document provides methods and materials for assessing and / or treating mammals (e.g., humans) having, or suspected of having, a spinal cord injury. For example, the presence of (a) spinal cord-derived cell free DNA (cfDNA) and / or (b) an elevated level of one or more of a fatty acid binding protein 3 (FABP3) polypeptide, a RE1-silencing transcription factor (REST) polypeptide, an interleukin 6 (IL-6) polypeptide, and a neurofilament, heavy polypeptide (NF-H) polypeptide in a fluid sample (e.g., a blood sample) obtained from a mammal (e.g., a human) can be used to identify that mammal as having a spinal cord injury. In some cases, a mammal (e.g., a human) identified as having a spinal cord injury as described herein can be administered one or more spinal cord injury treatments.

The invention discloses an electrochemical sensor for IBD protein marker detection as well as a preparation method and application of the electrochemical sensor. The electrochemical sensor is composed of a semi-cured PDMS flexible substrate in which CNT is embedded, deposited gold nanoparticles and a nucleic acid sensing layer, the nucleic acid sensing layer comprises a tumor necrosis factor-alpha sensor, an interleukin 6 sensor, an interleukin 8 sensor, a transforming growth factor beta1 sensor, a reference electrode and a counter electrode; the tumor necrosis factor-alpha sensor, the interleukin 6 sensor, the interleukin 8 sensor and the transforming growth factor beta1 sensor all adopt aptamer single chains modified by signal molecule methylene blue, and correspondingly adopt nucleotide sequences shown in SEQ ID NO.1-4. Matching and excellent biocompatibility of the sensor and human tissue modulus can be improved, and accurate detection of low-concentration biomarkers and stable signal output of the sensor under the strain working condition are achieved.

The present invention relates to compositions for detecting a lung cancer disease, comprising peptide affinity ligands for detecting different combinations of proteins of different groups of biomarkers which include CYFRA 21-1, Prolactin, Squamous Cell Carcinoma Antigen (SCC), Her2 / Neu, Cancer antigen 125 (CA125), carcinoembryonic antigen (CEA), C- reactive protein (CRP), Neuron Specific Enolase (NSE), C4 complement (C4), Interleukin 6 (IL-6), and Metallopeptidase Inhibitor 1 (TIMP-1). The invention further relates to methods of detecting or subtyping lung diseases, as well as to computer-implemented methods based on machine learning methods using expression data of the biomarkers.

The invention discloses a combined marker for risk assessment of active tuberculosis and application of the combined marker. The combined marker comprises interleukin 6, a chemotactic factor ligand 9, a chemotactic factor ligand 10 and a vascular endothelial growth factor. According to the disclosure, the combined marker for evaluating the risk of active tuberculosis of the subject and the application thereof can be provided.

The biosensor for simultaneously detecting cardiac troponin I and interleukin 6 comprises an indium tin oxide electrode, and two sensing areas with independent functions, namely an area I and an area II, are integrated on a single indium tin oxide electrode; the area I is modified with a cardiac troponin I binding aptamer, rhodamine B and a cadmium sulfide and bismuth tungstate composite material, and is used for detecting the cardiac troponin I aptamer through photoelectrochemical and colorimetric-fluorescence double signals; the region II is modified with an interleukin-6 binding aptamer and methylene blue silicon dioxide and is used for detecting interleukin-6 through photoelectrochemical and electrochemical double signals. The sensor and the detection method are good in accuracy and reliability.

The present disclosure relates to a cosmetic composition containing an extract of Cyperus rotundus extracted using warm microbubbles. The extract inhibits nitric oxide (NO) production and exhibits excellent anti-inflammatory efficacy by inhibiting the expression of interleukin 6 (IL-6), cyclooxygenase-2 (COX-2), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α), which are inflammatory expression factors. In addition, the extract enhances the expression of aquaporin-3 (AQP-3), hyaluronan synthase 2 (HAS-2), claudin-1 (CLDN-1), cadherin 1 (CDH1), filaggrin (FLG), and involucrin (IVL), which are genes related to the skin barrier and moisturizing. Thus, when using the extract for cosmetic products, excellent effects can be exhibited in skin soothing, moisturizing, enhancement of the skin barrier, relief of irritation such as erythema, relief of pruritus, and the like, so the extract can be usefully applied to multi-care products that improve skin conditions.

Methods of treating subjects suffering from non-alcoholic steatohepatitis (NASH) by interfering with epidermal growth factor (EGFR) and interleukin 6 (IL-6) production and / or function in hepatic stellate cells.

The application belongs to the field of biological medicine, and particularly relates to application of an extract of Pteronura dumerelli in preparation of a medicine for treating ulcerative colitis, and aims to solve the technical problems of weak mucosa repair capacity, high recurrence rate after drug withdrawal, prominent long-term application safety problem, poor drug response or drug resistance of part of patients, and poor economic accessibility of existing ulcerative colitis treatment medicines. The preparation of the extract comprises the following steps: edible soft tissues of Pteronura dumerelli are washed with clean water to remove impurities, and then subjected to tissue crushing and homogenization treatment in a preset low-temperature environment; a compound enzyme system composed of neutral protease and papain is added to perform mild limited enzymolysis, and active small-molecule peptides and polysaccharide components are reserved; after low-temperature centrifugation to remove precipitates, two-stage ultrafiltration membranes are used for grading purification, high-activity small-molecule anti-inflammatory repair components are enriched, and finally low-temperature vacuum concentration and sterile filtration are performed to obtain a light yellow water-soluble active extract. The extract can inhibit activation of a nuclear factor kappa B inflammatory pathway, down-regulate levels of tumor necrosis factor alpha, interleukin 6 and interleukin 1 beta proinflammatory factors, reduce intestinal inflammatory cascade reaction, up-regulate expression of tight junction proteins Occludin and Claudin-1, repair damaged intestinal epithelial barrier, promote ulcer mucosa regeneration and healing, and realize a double synergistic treatment effect of anti-inflammation and mucosa repair.

The invention provides a special culture medium for lung cancer organoid and a culture method thereof, and belongs to the technical field of biotechnology. The invention relates to a special culture medium for lung cancer organoid, which consists of a basic culture medium and a culture additive, and the basic culture medium is an Advanced DMEM / F12 culture medium, the culture additives comprise an epidermal growth factor, a basic fibroblast growth factor, a keratinocyte growth factor, a fibroblast growth factor 10, insulin, SB202190, an insulin-like growth factor 1, B27, nicotinamide, N-acetylcysteine, hydrocortisone, Y-27632, retinoic acid and interleukin 6. According to the special culture medium for the lung cancer organoids, the culture success rate of the lung cancer organoids is increased while the culture cost is reduced.

In view of the current situation of probiotics for periodontitis treatment in the prior art, the application provides a Weissella confusa LHJY. The Weissella confusa LHJY strain is named as Weissella confusa LHJY strain, is preserved in the China Center for Type Culture Collection, and has a preservation number of CCTCC NO: M 20251930 and a preservation date of September 1, 2025. The inventors isolate and purify the probiotic Weissella confusa LHJY from a pickled vegetable sample; and find that the Weissella confusa LHJY has a significant inhibitory effect on P. gingivalis and F. nucleatum, which are important periodontal pathogenic bacteria, through a bacteriostatic experiment and a biofilm removal experiment, thereby filling the blank of application of the Weissella confusa to periodontitis treatment in the prior art. Moreover, the Weissella confusa LHJY can tolerate a high concentration of lysozyme, effectively reduces the expression of interleukin 1β, tumor necrosis factor α and interleukin 6 inflammatory factors in an inflammatory cell model, and has an important application prospect in inhibiting periodontal disease pathogenic bacteria and regulating immune responses.

The application provides a prostate cancer organoid special culture medium and a culture method thereof, and belongs to the technical field of biological medicine. The prostate cancer organoid special culture medium is composed of a basic culture medium and a culture additive. The basic culture medium does not contain exogenous added Noggin recombinant protein and R-spondin recombinant protein. The culture additive comprises basic fibroblast growth factor, keratinocyte growth factor, fibroblast growth factor 10, insulin, p38MAPK signal pathway inhibitor, insulin-like growth factor 1, B27, nicotinamide, N-acetylcysteine, hydrocortisone, ROCK kinase inhibitor, retinoic acid, interleukin 6, prostaglandin E2, forskolin and androgen. The prostate cancer organoid special culture medium can reduce the cost and improve the culture success rate.

A recombinant nucleic acid molecule is encoded at least by an ORF to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one first hairpin loop structure, at least one second hairpin loop structure and a first promoter. The first and second hairpin loop structure regulates an amount of Granulocyte monocyte colony stimulating factor (GMCSF) cytokine and Interleukin 6 (IL6) cytokine, respectively. The first hairpin loop structure is formed by at least two first short hairpin RNA sequences and at least one microRNA30 sequence. The second hairpin loop structure is formed by at least two second short hairpin RNA sequences and at least one microRNA30 sequence. The first promoter is disposed upstream of the first and second hairpin loop structure.